Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATXSNASDAQ:COLLNASDAQ:ETNBNASDAQ:MLYS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATXSAstria Therapeutics$5.76+2.7%$4.86$3.56▼$12.92$316.60M0.39365,319 shs199,361 shsCOLLCollegium Pharmaceutical$30.11+0.8%$28.69$23.23▼$42.29$960.10M0.63401,931 shs225,794 shsETNB89BIO$9.81-1.9%$8.69$4.16▼$11.84$1.46B1.31.51 million shs1.15 million shsMLYSMineralys Therapeutics$14.14+2.7%$14.85$8.24▼$18.38$897.46M-0.17534,490 shs767,630 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATXSAstria Therapeutics+2.67%+1.05%+46.94%-5.73%-37.25%COLLCollegium Pharmaceutical+0.77%+2.28%+4.33%+0.50%-4.93%ETNB89BIO-1.90%-1.31%+3.37%+22.32%+16.09%MLYSMineralys Therapeutics+2.69%+2.61%-11.40%-12.45%+11.96%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationATXSAstria Therapeutics1.987 of 5 stars3.62.00.00.01.91.70.0COLLCollegium Pharmaceutical3.6988 of 5 stars3.41.00.03.01.50.81.9ETNB89BIO2.0921 of 5 stars3.53.00.00.01.10.80.6MLYSMineralys Therapeutics2.849 of 5 stars3.43.00.00.02.04.20.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATXSAstria Therapeutics 3.25Buy$30.00420.83% UpsideCOLLCollegium Pharmaceutical 2.75Moderate Buy$43.7545.30% UpsideETNB89BIO 3.00Buy$26.43169.40% UpsideMLYSMineralys Therapeutics 2.75Moderate Buy$32.25128.08% UpsideCurrent Analyst Ratings BreakdownLatest ATXS, ETNB, COLL, and MLYS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/17/2025MLYSMineralys TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$42.006/13/2025ATXSAstria TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.006/11/2025ETNB89BIOWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)6/10/2025MLYSMineralys TherapeuticsJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageHold$15.005/24/2025ETNB89BIOWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)5/14/2025MLYSMineralys TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$48.005/14/2025ATXSAstria TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$47.00 ➝ $47.005/13/2025MLYSMineralys TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$42.00 ➝ $42.005/10/2025ETNB89BIOWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)5/9/2025COLLCollegium PharmaceuticalPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$36.00 ➝ $37.004/30/2025ETNB89BIOCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy(Data available from 6/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATXSAstria TherapeuticsN/AN/AN/AN/A$3.97 per shareN/ACOLLCollegium Pharmaceutical$631.45M1.53$12.44 per share2.42$7.10 per share4.24ETNB89BION/AN/AN/AN/A$3.34 per shareN/AMLYSMineralys TherapeuticsN/AN/AN/AN/A$3.84 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATXSAstria Therapeutics-$94.26M-$1.87N/AN/AN/AN/A-47.18%-31.26%8/11/2025 (Estimated)COLLCollegium Pharmaceutical$69.19M$1.2224.685.00N/A6.61%99.08%15.14%8/6/2025 (Estimated)ETNB89BIO-$367.08M-$3.38N/AN/AN/AN/A-81.44%-70.17%8/4/2025 (Estimated)MLYSMineralys Therapeutics-$177.81M-$3.73N/AN/AN/AN/A-71.15%-65.71%8/12/2025 (Estimated)Latest ATXS, ETNB, COLL, and MLYS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025ATXSAstria Therapeutics-$0.48-$0.58-$0.10-$0.58N/AN/A5/12/2025Q1 2025MLYSMineralys Therapeutics-$1.02-$0.79+$0.23-$0.79N/AN/A5/8/2025Q1 2025COLLCollegium Pharmaceutical$1.50$1.49-$0.01$0.07$174.96 million$177.76 million5/1/2025Q1 2025ETNB89BIO-$0.50-$0.49+$0.01-$0.49N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATXSAstria TherapeuticsN/AN/AN/AN/AN/ACOLLCollegium PharmaceuticalN/AN/AN/AN/AN/AETNB89BION/AN/AN/AN/AN/AMLYSMineralys TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATXSAstria TherapeuticsN/A17.3917.39COLLCollegium Pharmaceutical3.301.081.01ETNB89BIO0.0618.0318.03MLYSMineralys TherapeuticsN/A26.4826.48Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATXSAstria Therapeutics98.98%COLLCollegium PharmaceuticalN/AETNB89BION/AMLYSMineralys Therapeutics84.46%Insider OwnershipCompanyInsider OwnershipATXSAstria Therapeutics4.50%COLLCollegium Pharmaceutical2.51%ETNB89BIO2.80%MLYSMineralys Therapeutics33.24%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATXSAstria Therapeutics3056.43 million53.89 millionOptionableCOLLCollegium Pharmaceutical21032.13 million31.33 millionOptionableETNB89BIO40145.98 million141.90 millionOptionableMLYSMineralys Therapeutics2865.18 million43.51 millionOptionableATXS, ETNB, COLL, and MLYS HeadlinesRecent News About These CompaniesEquities Analysts Offer Predictions for MLYS Q2 EarningsJune 21, 2025 | americanbankingnews.comResearch Analysts Issue Forecasts for MLYS Q2 EarningsJune 19, 2025 | marketbeat.comMineralys enhances lorundrostat data package ahead of planned NDAJune 18, 2025 | thepharmaletter.comPromising Trial Results for Lorundrostat Boost Mineralys Therapeutics’ Investment AppealJune 18, 2025 | tipranks.comMineralys Therapeutics (NASDAQ:MLYS) Given Buy Rating at HC WainwrightJune 18, 2025 | americanbankingnews.comMineralys Therapeutics: Investigational Drug Shows Benefit In Hypertensive Patients With Chronic Kidney Disease, Stock JumpsJune 17, 2025 | benzinga.comMineralys Therapeutics (NASDAQ:MLYS) Stock Price Up 5.6% - Should You Buy?June 17, 2025 | marketbeat.comMineralys Therapeutics' (MLYS) Buy Rating Reaffirmed at HC WainwrightJune 17, 2025 | marketbeat.comPositive Phase II Results for Mineralys Therapeutics’ Lorundrostat Support Buy RatingJune 17, 2025 | tipranks.comMineralys' hypertension drug continues winning streak, lowering blood pressure in phase 2June 17, 2025 | fiercebiotech.comMineralys Therapeutics stock jumps after positive kidney disease trial dataJune 17, 2025 | investing.comMineralys Therapeutics Shares Climb on Strong Results from Kidney Disease TrialJune 17, 2025 | msn.comMineralys Therapeutics Announces Positive Topline Results from Phase 2 Explore-CKD Trial of Lorundrostat for the Treatment of Hypertension in Subjects with CKD and AlbuminuriaJune 17, 2025 | globenewswire.comMineralys Therapeutics (NASDAQ:MLYS) Shares Down 4.5% - Should You Sell?June 16, 2025 | marketbeat.comMineralys Therapeutics (NASDAQ:MLYS) Cut to Sell at Wall Street ZenJune 14, 2025 | marketbeat.comJefferies initiates Mineralys Therapeutics stock with hold ratingJune 12, 2025 | uk.investing.comJefferies Initiates Coverage of Mineralys Therapeutics (MLYS) with Hold RecommendationJune 12, 2025 | msn.comWellington Management Group LLP Has $1.13 Million Stock Position in Mineralys Therapeutics, Inc. (NASDAQ:MLYS)June 7, 2025 | marketbeat.comMineralys Therapeutics: Merits A Small 'Speculative' HoldingJune 3, 2025 | seekingalpha.comMineralys Therapeutics (NASDAQ:MLYS) Stock Price Down 4.9% - Should You Sell?May 31, 2025 | marketbeat.comPolar Asset Management Partners Inc. Raises Stake in Mineralys Therapeutics, Inc. (NASDAQ:MLYS)May 28, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeIntel's Turnaround Strategy Shifts From Planning to Attack ModeBy Jeffrey Neal Johnson | June 20, 2025View Intel's Turnaround Strategy Shifts From Planning to Attack ModeBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI DefenseTesla Bulls and Bears Collide: What Investors Should KnowBy Sam Quirke | June 18, 2025View Tesla Bulls and Bears Collide: What Investors Should KnowATXS, ETNB, COLL, and MLYS Company DescriptionsAstria Therapeutics NASDAQ:ATXS$5.76 +0.15 (+2.67%) Closing price 06/24/2025 04:00 PM EasternExtended Trading$5.77 +0.01 (+0.24%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, an immune disorder associated with loss of skin barrier function and itching. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is headquartered in Boston, Massachusetts.Collegium Pharmaceutical NASDAQ:COLL$30.11 +0.23 (+0.77%) Closing price 06/24/2025 04:00 PM EasternExtended Trading$30.12 +0.01 (+0.05%) As of 04:06 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.89BIO NASDAQ:ETNB$9.81 -0.19 (-1.90%) Closing price 06/24/2025 04:00 PM EasternExtended Trading$9.81 0.00 (-0.04%) As of 06/24/2025 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.Mineralys Therapeutics NASDAQ:MLYS$14.14 +0.37 (+2.69%) Closing price 06/24/2025 04:00 PM EasternExtended Trading$14.13 -0.01 (-0.07%) As of 06/24/2025 04:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 Hot Trades for Insiders, But Are They Good Buys for Investors? Why Qualcomm’s Latest Price Target Can't Be Ignored Texas Instruments Stock: Congress Likes It, Should You Too? Geospace Stock Skyrockets After Major Petrobras Contract Analyst Sees Meta Hitting $800: What May Lead Shares to New Highs CrowdStrike Eyes Breakout as Cyber Threats Boost Demand Reddit Stock Ignites: Surge in Call Options Signals Big Bet Microsoft Stock Holds Steady as AI Drives Workforce Shift Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
